Clinical trials: Epigenetic Therapy
Periodontitis
Epigenetics and Periodontal Treatment
Objective: The aim of this pilot study is to evaluate the alterations of epigenetic patterns in periodontally diseased individuals, before and after periodontal treatment, also in comparison to periodontally healthy patients.
- Trial name
- NCT02835898
- Testing
- Conventional periodontal treatment
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Milan
Myelodysplastic Syndrome
A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome
The purpose of this study is to evaluate the effectiveness and safety of decitabine (Dacogen) intravenous injection in patients with Myelodysplastic Syndrome.
- Trial name
- NCT01041846
- Testing
- No intervention
- Volunteers
- 103 people
- Sponsor
- Janssen Korea, Ltd., Korea
Crohn Disease (CD)
A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease
This is a multicentre, prospective, randomised, controlled, open-label study to assess the efficacy, safety, and cost-effectiveness of epigenome-guided treatment selection compared to usual standard-of-care (SOC) treatment…
- Trial name
- OMICROHN (NCT07363044)
- Testing
- Epigenome-Guided Treatment Arm, Investigator-Guided Treatment Arm
- Where
- 51 sites in Belgium, Hungary and 4 more
- Volunteers
- 378 people
- Sponsor
- Alimentiv Inc.
Smoking Cessation, Smoking Cessation Intervention
Unraveling the Genetic Basis of Nicotine Addiction for Novel Therapeutic Strategies
This case-control study aims to investigate the genetic and molecular bases of nicotine addiction to identify potential therapeutic targets.
- Conditions
- Smoking Cessation, Smoking Cessation Intervention, Nicotine Addiction, Epigenetics
- Trial name
- NicoGen (NCT06471387)
- Testing
- Flexiquit Smoking Cessation Intervention
- Where
- Cyprus
- Volunteers
- 200 people
- Sponsor
- University of Cyprus
Colo-rectal Cancer
Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer
NO-CUT is a one-stage phase II trial seeking to establish whether an oxaliplatin-based chemotherapy preceding standard neo-adjuvant fluoropyrimidines-based chemo radiotherapy, can safely spare demolitive surgical intervention in…
- Trial name
- NO-CUT (NCT03565029)
- Testing
- XELOX, Radiotherapy
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Niguarda Hospital
Colorectal Cancer, Colorectal Cancer Metastatic
Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy
This is a prospective study investigating the disease course of patients with colorectal cancer that have had their cancer spread to their liver.
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic, Hepatic Metastases
- Trial name
- COMPARISON (NCT03364621)
- Where
- 2 sites in Canada
- Volunteers
- 17 people
- Sponsor
- University Health Network, Toronto
Head and Neck Squamous Cell Carcinoma
Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC
A two-part molecular epidemiological study will be conducted to comprehensively assess the association between miR expression and miR promoter methylation and the response to therapy and prognosis in primary, HPV-negative HNSCC…
- Trial name
- NCT03953443
- Testing
- Not interventional
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New Mexico Cancer Research Alliance
Peripheral T Cell Lymphoma, Epigenetic Repression
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
This study is investigating the effectiveness (specifically the objective response rate - ORR) of a new combination therapy called CAMP (chidamide, azacitidine, liposomal mitoxantrone, and prednisone) for previously untreated…
- Trial name
- NCT05958719
- Testing
- Chidamide, Azacitidine, liposomal mitoxantrone
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Nephrotic Syndrome Steroid-Dependent, Nephrotic Syndrome Steroid-Resistant
Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study
Idiopathic Nephrotic Syndrome is a rare disease of the kidneys, which typically affects children. For most affected children there is the need of a prolonged treatment with drugs reducing the activity of the immune system, also…
- Conditions
- Nephrotic Syndrome Steroid-Dependent, Nephrotic Syndrome Steroid-Resistant, Nephrotic Syndrome in Children, Glomerulonephritis
- Trial name
- PRECISE (NCT06792448)
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Adult Brain Tumor, Lung Cancer
Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
This research trial studies metabolomic and other molecular profiling to identify predictive biomarkers for radiation toxicity and survival in patients with lung or brain cancers receiving radiation therapy.
- Conditions
- Adult Brain Tumor, Lung Cancer, Radiation Toxicity
- Trial name
- NCT02259218
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 273 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cystic Fibrosis (CF)
Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.
Cystic Fibrosis (CF) is a genetic disease that affects multiple organs and systems. In recent years, the marketing of CFTR protein modulator drugs, such as the Elexacaftor-Tezacaftor-Ivacaftor (ETI) combination, has significantly…
- Trial name
- NCT07363304
- Testing
- Elexacaftor, Tezacaftor, Ivacaftor
- Where
- 6 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Meyer Children's Hospital IRCCS
Pancreatic Cancer, Metastasis
Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)
This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression.
- Conditions
- Pancreatic Cancer, Metastasis, Epigenetic
- Trial name
- mirPANC 2 (NCT06945978)
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Benedito Mauro Rossi
Metastatic Cervical Cancer
Hydralazine Valproate for Cervical Cancer
The current standard for recurrent, persistent or metastatic cervical cancer is palliative chemotherapy with cisplatin topotecan, however, the results need to be improved.
- Trial name
- NCT00532818
- Testing
- Hydralazine and magnesium valproate
- Where
- Mexico
- Volunteers
- 143 people
- Sponsor
- National Institute of Cancerología
Long COVID-19 Syndrome, Long COVID Symptoms
Epigenetic Changes in Long COVID Patients
The goal of this observational study is to improve the understanding of the biological mechanisms underlying long COVID and to identify molecular biomarkers that may support its diagnosis, prognosis, and future precision medicine…
- Trial name
- ECLIPSE (NCT07757620)
- Where
- 3 sites in Italy
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The purpose of the study is to determine how effective azacitidine, MGCD0103, and the combination of azacitidine and MGCD0103 are in treating AML or MDS in people over 60 years of age.
- Trial name
- NCT00666497
- Testing
- Azacitidine, MGCD0103
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 6 people
- Sponsor
- Mirati Therapeutics Inc.
Non-Small Cell Lung Cancer, Epigenetic Therapy
Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
Response Rate
- Trial name
- NA_00084192 (NCT01928576)
- Testing
- Azacitidine, Entinostat, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 143 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma
Epigenetic Changes in Hepatocellular Carcinoma Developed After Direct Acting Antiviral Therapy for Chronic Hepatitis C
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, its survival rate ranks only second to lung cancer and it is a severe threat to human health. In Egypt, HCC constitutes a significant public health problem.
- Trial name
- NCT04220151
- Testing
- DNA methylation
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
T-cell Lymphoma, Aggressive B-cell Lymphoma
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
The purpose of this study is to evaluate how well the study drug works and safety of oral decitabine in patients with refractory or relapsed lymphoid malignancies.
- Conditions
- T-cell Lymphoma, Aggressive B-cell Lymphoma, Non-Hodgkin's Lymphomas, Indolent B-cell Lymphoma
- Trial name
- NCT02846935
- Testing
- Decitabine, Tetrahydrouridine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Yogen Saunthararajah
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Azacitidine has proved prolonged overall survival in patients with high-risk MDS. Minor pilot studies have shown that treatment with Azacitidine can induce transfusion independency in previous transfusion dependent patients with…
- Trial name
- NCT01048034
- Testing
- Azacitidine, Erythropoetin
- Where
- 17 sites in Denmark, Norway and 1 more
- Volunteers
- 30 people
- Sponsor
- Nordic MDS Group
Colorectal Cancer Metastatic
ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
The investigators hypothesize that the epigenetic agent valproic acid improve the activity of anti-EGFR agents, prevent and revert the emergence of EGFR resistance, in a rechallenge setting.
- Trial name
- VICTORIA (NCT06714357)
- Testing
- irinotecan, panitumumab, Valproic Acid (VPA)
- Where
- 8 sites in Italy
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute, Naples